α-Melanocyte stimulating hormone analogues: The perils and the promise

Journal of Drugs in Dermatology

Volumn 8, Issue 8, 2009, Pages 772-776

  Mazza, Joni M ^a   Zippin, Jonathan H ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; MELANIN; RETINOID; ALPHA INTERMEDIN; DRUG DERIVATIVE;

ACTINIC KERATOSIS; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPOIETIC PROTOPORPHYRIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HISTOPATHOLOGY; HUMAN; LETHARGY; MELANOGENESIS; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHOTODYNAMIC THERAPY; PUVA; REVIEW; SKIN PROTECTION; SOLAR URTICARIA; SUN EXPOSURE; VOMITING; ANIMAL; CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; METABOLISM; PATHOPHYSIOLOGY; SKIN; SKIN DISEASE; SKIN PIGMENTATION;

ALPHA-MSH; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MELANINS; PROTOPORPHYRIA, ERYTHROPOIETIC; SKIN; SKIN DISEASES; SKIN PIGMENTATION;

EID: 70349254751     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte- stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med. 2009;360(3):306-307.
2. Bolognia J, Lorizzo, JL, Rapini, RP. Dermatology. Vol 2. 2nd ed. Spain: Elsevier Limited; 2008.
3. Virador VM, Muller J, Wu X, et al. Influence of alpha-melanocyte- stimulating hormone and ultraviolet radiation on the transfer of melanosomes to keratinocytes. FASEB J. 2002;16(1):105-107.
4. Gilchrest BA, Eller MS. DNA photodamage stimulates melanogenesis and other photoprotective responses. J Investig Dermatol Symp Proc. 1999;4(1):35-40. (Pubitemid 29491252)
5. Lerner AB, McGuire JS. Effect of alpha- and betamelanocyte stimulating hormones on the skin colour of man. Nature. 1961;189:176-179.
6. Levine N, Dorr RT, Ertl GA, et al. Effects of a potent synthetic melanotropin, Nle4-D-Phe7-alpha-MSH (Melanotan-I) on tanning: A dose-ranging study. J Dermatolog Treat. 1999;10:127-132. (Pubitemid 29348532)
7. Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-DPhe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72(4):526-532.
8. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte- stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126(8):1869-1878. (Pubitemid 44086522)
9. Ros AM, Wennersten G. Current aspects of polymorphous light eruptions in Sweden. Photodermatol. 1986;3(5):298-302. (Pubitemid 17217334)
10. Morison WL, Stern RS. Polymorphous light eruption: A common reaction uncommonly recognized. Acta Derm Venereol. 1982;62(3):237-240. (Pubitemid 12112915)
11. Honigsmann H. Polymorphous light eruption. Photodermatol Photoimmunol Photomed. Jun 2008;24(3):155-161. (Pubitemid 351682233)
12. Richards HL, Ling TC, Evangelou G, et al. Psychologic distress in polymorphous light eruption and its relationship to patients' beliefs about their condition. J Am Acad Dermatol. 2007;56(3):426-431. (Pubitemid 46273850)
13. Clinuvel Launches New Phase II. 23 September 2008. http://www. biotechnologynews.net/storyview.asp?storyid=269987.Accessed May 30, 2009.
14. Clinuvel Pharmaceuticals Limited. Annual Report 2008. www.clinuvel.com/resources/pdf/annual-reports/2008/annual-report-2008.pdf. Accessed May 30, 2009.
15. McDonald K. Cliuvel moves to phase III for PLE. 25 January 2007 http://www.lifescientist.com.au/article/173228/clinuvel-moves-phase-iii-ple. Accessed 30 May 2009.
16. Ethics approval for sun drug in sunny Manchester 12 June 2008 http://www.biotechnologynews.net/storyview.asp?storyid=264799. Accessed 30 May 2009.
17. Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg. 1997;23(11):1009-1019.
18. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: Evidence and evolving classification schemes. Clin Dermatol. 2004;22(3):189-196. (Pubitemid 38950745)
19. Evans N. New trial for Clinuvel's suntan drug. 01 November 2007. http://www.biotechnologynews.net/storyview.asp?storyid=115536. Accessed 30 May 2009.
20. Clinuvel's drug begins global phase II skin cancer trials. 05 November 2007. http://www.medicalnewstoday.com/articles/87708.php. Accessed 30 May 2009.
21. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.
22. Jiang J, Sharma SD, Nakamura S, et al. The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res. 1995;8(6):314-323.
23. Gehlsen KR, Hadley ME, Levine N, et al. Effects of a melanotropic peptide on melanoma cell growth, metastasis, and invasion. Pigment Cell Res. 1992;5(5 Pt 1):219-223.
24. Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. Apr 2009;145(4):441-444.
25. Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed "sun tan jab". BMJ. 2009;338:b277.